Phase III Trials In Glioblastoma Multiforme
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug development for the complex, rare and aggressive orphan cancer glioblastoma multiforme is fraught with challenges and few compounds make it through registrational studies. Contenders in the space include Roche/Genentech's Avastin (bevacizumab) and EMD Serono's cilengitide. Research aimed at making better use of one of the few drugs that is approved and used in GBM - Merck's standard-of-care treatment Temodar (temozolomide) - is also ongoing. Sources: Elsevier Business Intelligence's Inteleos drug development database, www.clinicaltrials.gov, company websites.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class